Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
125 participants
INTERVENTIONAL
2019-01-01
2021-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
OTHER
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Sebacia Microparticles Treatment
Sebacia Microparticles Treatment
Sebacia Microparticles procedure involving microparticles and 1064 nm laser. Three treatment procedures over a two-week period.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Sebacia Microparticles Treatment
Sebacia Microparticles procedure involving microparticles and 1064 nm laser. Three treatment procedures over a two-week period.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Between 10 and 50 papules/pustules
* Fitzpatrick skin phototype I, II or III
* Able to provide informed consent and comply with study schedule and other requirements
Exclusion Criteria
* Nodulocystic acne, significant scarring or excoriation
* Requires oral retinoid, antibiotic or corticosteroid for acne
* New or fluctuating hormone or hormone-regulating therapy
* Photosensitivity or allergy to gold
* Medical or mental health condition that would pose a risk to patient or impair treatment and evaluation
12 Years
45 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Sebacia, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
VP, Clinical & Regulatory Affairs
Role: STUDY_DIRECTOR
Sebacia, Inc.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Miami Dermatology & Laser Institute
Miami, Florida, United States
Dermatology Institute of Boston
Boston, Massachusetts, United States
International Clinical Research
Murfreesboro, Tennessee, United States
Austin Institute for Clinical Research - Central
Austin, Texas, United States
Austin Institute for Clinical Research - Pflugerville
Pflugerville, Texas, United States
Premier Clinical Research
Spokane, Washington, United States
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
Company Website
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SEB-0550
Identifier Type: -
Identifier Source: org_study_id